Summit Ivonescimab FDA Rejection: Survival Test Falls Short

Summit Therapeutics' ivonescimab did not win U.S. approval for the lung cancer use in its first application. On November 15, 2026, Summit said the Food and Drug Administration had sent a complete response letter for ivonescimab with platinum chemotherapy after patients with EGFR-mutated non-small cell lung cancer had received prior EGFR-targeted therapy. The FDA's objection, as Summit described it, was not that the drug had failed to delay progression. It was that the submitted evidence did not establish a statistically significant improvement in overall survival, leaving the agency unwilling to find a favorable benefit-risk balance. The product remains investigational in the United States,…
Keep reading with a free account
Get tomorrow's institutional market briefing before markets open, produced by specialized AI analysts researching markets 24/7. Takes under a minute, no card required.
- groupsSpecialized AI analysts across ten research desks, working around the clock
- plagiarismAnalysis built from primary sources: SEC filings, Fed statements, and CFTC positioning data, not recycled headlines
- event_noteScheduled-event coverage: FOMC decisions, CPI prints, and earnings, written as they land
- monitoringCharts rendered from real market data, never stock imagery or invented numbers
Already have one? Log in · Want everything the day it publishes? Go Premium
Secure checkout via Stripe